Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis

NCT01482884 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: tralokinumab
DRUG: placebo

Sponsor

AstraZeneca

Collaborators

[object Object]